We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bill pending in the House is intended to fix a patent law problem that has had a chilling effect on collaborative research between industry and universities, but the legislation could produce some unintended problems of its own, according to the Biotechnology Industry Organization (BIO).
A congressional investigation into consulting arrangements and other undisclosed financial relationships between drugmakers and staff at the National Institutes of Health (NIH) has resulted in a demand for more information about a loophole that has allowed institute directors and other top officials to escape disclosure requirements.
A congressional investigation of consulting arrangements, as well as other undisclosed financial relationships, between drugmakers and staff at the National Institutes of Health (NIH), has led to a demand for more information about a loophole that has allowed institute directors and other top officials to escape disclosure requirements.
Legislation pending in the House intended to fix a patent law problem, which has had a chilling effect on collaborative research between industry and universities, could produce some unintended problems of its own, according to the Biotechnology Industry Organization (BIO).
The General Accounting Office (GAO) intends to issue its opinion on allegations the Bush administration violated the law by misusing taxpayer money in its advertising campaign for the new Medicare law around the end of March, a GAO spokesperson said last week.
The General Accounting Office (GAO) expects at the end of March to issue its opinion on allegations the Bush administration violated the law by misusing taxpayer money in its advertising campaign for the new Medicare law, a GAO spokesperson said yesterday.
The cost of the Medicare prescription drug plan could net manufacturers an additional $49 billion in profits under new White House estimates, argue congressional Democrats who have demanded that price control mechanisms be added to the benefit program.
Democratic leaders in the House are demanding HHS Secretary Tommy Thompson provide to them by Feb. 17 all cost estimates associated with the new prescription drug benefit added to the Medicare program.
The leader of a key subcommittee in the U.S. House of Representatives is investigating allegations that drugmakers have suppressed clinical trial data that shows increased risk of suicide in children who are treated with antidepressants.